Showing results (1-10 of 6) with videos related to
Sort By:
Pageof 1
Trends in Molecular Medicine|September 6, 2025
Targeting pathological ERK1/2 signaling in cancer and beyondConstanze Schanbacher, Maria-Elisabeth Goebeler, Brenda Gerull, et al.Biomedicines|February 25, 2023
Complement 1q/Tumor Necrosis Factor-Related Proteins (CTRPs): Structure, Receptors and SignalingConstanze Schanbacher, Heike M Hermanns, Kristina Lorenz, et al.International Journal of Molecular Sciences|January 21, 2022
ERK1/2 Activity Is Critical for the Outcome of Ischemic StrokeConstanze Schanbacher, Michael Bieber, Yvonne Reinders, et al.Pharmacological Research|January 1, 2025
From Ca<sup>2</sup><sup>+</sup> dysregulation to heart failure: β-adrenoceptor activation by RKIP postpones molecular damages and subsequent cardiac dysfunction in mice carrying mutant PLN<sup>R9C</sup> by correction of aberrant Ca<sup>2+</sup>-handlingTheresa Brand, Bettina Tanitha Baumgarten, Sabrina Denzinger, et al.Circulation Research|November 2, 2016
Phosphodiesterase 2 Protects Against Catecholamine-Induced Arrhythmia and Preserves Contractile Function After Myocardial InfarctionChristiane Vettel, Marta Lindner, Matthias Dewenter, et al.Nature Communications|April 9, 2020
Interference with ERK-dimerization at the nucleocytosolic interface targets pathological ERK1/2 signaling without cardiotoxic side-effectsAngela Tomasovic, Theresa Brand, Constanze Schanbacher, et al.Pageof 1